The National Bank for Economic and Social Development (BNDES) approved the investment of R$200 million to finance Libbs Farmacêutica’s national machinery, equipment and industrialized goods. The announcement was made this Wednesday (11), during the inauguration of the Biotec Pilot Plant and the start of operation of the first High Potency Medicines Factory, in Embu das Artes (SP).
With the financing, Libbs plans to increase production capacity to triple gross revenue by 2032. By improving the manufacturing structure, the company will meet the demand for drugs produced by optimizing production lines.
The products include chemically synthesized and biological medicines for treating different types of cancer, as well as active pharmaceutical ingredients (“IFAs”) for personal use.
“We want to consolidate our position as developers of innovative biological medicines, in addition to strengthening science in the country through partnerships and co-development of products”, stated the president of Libbs, Alcebíades Athayde Junior.
The director of Productive Development, Innovation and Foreign Trade at BNDES, José Luís Gordon, highlighted that the investments approved by the bank are part of the national strategy to develop and strengthen the economic-industrial health complex.
In the pharmaceutical industry segment alone, the total approved by BNDES until November 2024 has already reached R$3.7 billion, a value 152% higher than that recorded in the entire year 2023 (R$1.5 billion).
“With the support of BNDES, the national industry is developing new medicines, pharmaceutical associations and vaccines, setting up research and development centers and purchasing machinery and equipment. From January 2023 to November 2024, the Bank’s credit approvals for the health industrial complex totaled R$5.7 billion, a record amount in the historical series that began in 1995”, highlighted the institution’s president, Aloizio Mercadante.
